The FDA is altering its COVID-19 vaccination strategy by prioritizing immunizations for high-risk individuals, including seniors and those with health issues, while requiring further studies for children and low-risk adults. This new approach, aimed at rebuilding public trust and aligned with international practices, will potentially reduce the pool of eligible vaccine recipients from 300 million to between 100 million and 200 million. The FDA also emphasizes a commitment to rigorous scientific evaluation of vaccine safety and efficacy.
The FDA's new Covid-19 philosophy represents a balance of regulatory flexibility and a commitment to gold-standard science.
We have launched down this multiyear campaign of booster after booster after booster and distrust of the American public.
The steps will bring the U.S. in line with approaches taken by other high-income countries and aim to restore trust in vaccines.
Additional studies would have to show the benefits of vaccination outweigh risks for adults and children not deemed high-risk.
Collection
[
|
...
]